Reciprocal action of interferon-gamma and interleukin-4 promotes granulomatous inflammation induced by Rhodococcus aurantiacus in mice.

Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0374672 Publication Model: Print Cited Medium: Print ISSN: 0019-2805 (Print) Linking ISSN: 00192805 NLM ISO Abbreviation: Immunology Subsets: MEDLINE

Original Publication: Oxford : Blackwell Scientific Publications

Rhodococcus*; Actinomycetales Infections/*immunology ; Granuloma/*immunology ; Interferon-gamma/*immunology ; Interleukin-4/*immunology; Animals ; Antibodies, Monoclonal/immunology ; Female ; Granuloma/microbiology ; Interleukin-4/biosynthesis ; Interleukin-4/genetics ; Mice ; Mice, Inbred Strains ; Polymerase Chain Reaction ; RNA, Messenger/genetics ; T-Lymphocyte Subsets/immunology

An intravenous injection of Rhodococcus aurantiacus to mice causes granulomatous inflammation dependent on endogenous interferon-gamma (IFN-gamma). The present study examined the role of endogenous interleukin-4 (IL-4) on granulomatous inflammation. Endogenous IL-4 in the spleen extracts was not detected during the phase of granuloma formation by enzyme-linked immunosorbent assay (ELISA). However, IL-4 protein level was elevated during the phase of granuloma regression. IL-4 mRNA expression in the livers and spleens was also elevated during the phase of granuloma regression. In addition, IL-4 levels during the phase of granuloma formation were increased by treatment with anti-IFN-gamma monoclonal antibody (mAb), suggesting that endogenous IFN-gamma might inhibit IL-4 production during the phase of granuloma formation. Administration of anti-IL-4 mAb on weeks 3 and 4 after the inoculation inhibited the regression of granulomas and augumented IFN-gamma level at 5 weeks. Endogenous IFN-gamma was produced by CD4+ T cells during the phase of granuloma regression and endogenous IL-4 was produced by both CD4+ and CD8+ T cells. These findings suggest that during the phase of granuloma formation endogenous IL-4 might be inhibited by IFN-gamma, while during the phase of granuloma regression endogenous IL-4 might play a crucial role in the reduction of granulomas and IFN-gamma production.

J Am Acad Dermatol. 1991 Feb;24(2 Pt 2):328-32. (PMID: 1999541)
Infect Immun. 1990 Jul;58(7):2386-8. (PMID: 2114368)
Infect Immun. 1991 Oct;59(10):3439-45. (PMID: 1680104)
J Immunol. 1992 Mar 15;148(6):1652-6. (PMID: 1347305)
J Immunol. 1992 Jun 15;148(12):3978-85. (PMID: 1602140)
Science. 1993 Jun 18;260(5115):1802-5. (PMID: 8511588)
Infect Immun. 1993 Jul;61(7):2872-8. (PMID: 8514390)
Cell. 1994 Jan 28;76(2):241-51. (PMID: 7904900)
Immunol Today. 1994 Mar;15(3):107-10. (PMID: 8172642)
Annu Rev Immunol. 1994;12:809-37. (PMID: 8011298)
J Exp Med. 1994 Aug 1;180(2):489-95. (PMID: 8046328)
Infect Immun. 1994 Dec;62(12):5498-504. (PMID: 7960131)
J Exp Med. 1994 Nov 1;180(5):1715-28. (PMID: 7525836)
Immunol Today. 1994 Dec;15(12):575-81. (PMID: 7848519)
Microbiol Immunol. 1995;39(7):499-507. (PMID: 8569535)
Immunol Rev. 1979;47:63-90. (PMID: 398327)
J Clin Microbiol. 1982 Oct;16(4):604-7. (PMID: 7153308)
J Immunol. 1983 Nov;131(5):2445-51. (PMID: 6415170)
Nature. 1985 May 23-29;315(6017):333-6. (PMID: 2582266)
J Clin Microbiol. 1985 Sep;22(3):472-4. (PMID: 4044805)
J Immunol. 1986 Apr 1;136(7):2348-57. (PMID: 2419430)
J Interferon Res. 1986 Oct;6(5):489-97. (PMID: 3100664)
Anal Biochem. 1987 Apr;162(1):156-9. (PMID: 2440339)
J Clin Microbiol. 1988 Feb;26(2):201-5. (PMID: 3343320)
J Immunol Methods. 1988 May 25;110(1):29-36. (PMID: 3131436)
J Exp Med. 1989 Jan 1;169(1):59-72. (PMID: 2521244)
Infect Immun. 1989 Nov;57(11):3331-7. (PMID: 2509360)
Clin Exp Immunol. 1991 Apr;84(1):92-6. (PMID: 1849808)

0 (Antibodies, Monoclonal)
0 (RNA, Messenger)
207137-56-2 (Interleukin-4)
82115-62-6 (Interferon-gamma)

Date Created: 19960701 Date Completed: 19961002 Latest Revision: 20190512

20250114

PMC1456344

10.1046/j.1365-2567.1996.d01-660.x

8774356